Non-erythroid effects of erythropoietin: Are neutrophils a target?

Leukemia Research

Volumn 33, Issue 10, 2009, Pages 1430-1432

  Avneon, Maayan ^a   Lifshitz, Lilach ^a   Katz, Odelia ^a   Prutchi Sagiv, Sara ^a   Gassmann, Max ^c   Mittelman, Moshe ^b   Neumann, Drorit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Erythropoietin; Inflammation; Murine models; Neutrophils

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD; BONE MARROW; CELL FUNCTION; CELL POPULATION; CONTROLLED STUDY; FEMALE; IMMUNOMODULATION; MOUSE; NEUTROPHIL; NEUTROPHIL COUNT; NONHUMAN; PERITONEAL CAVITY; PRIORITY JOURNAL; SPLEEN; TARGET CELL; TRANSGENIC MOUSE; TREATMENT DURATION;

ANIMALS; BONE MARROW; CELL MOVEMENT; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEUTROPHILS; REACTIVE OXYGEN SPECIES;

EID: 67649361763     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.03.020     Document Type: Article

References (8)

1. Prutchi-Sagiv S., Neumann D., and Mittelman M. Erythropoietin as an immunomotherapeutic agent: New uses for an old drug?. Med Hypoth Res 2 (2005) 587-596
2. Mittelman M., Neumann D., Peled A., Kanter P., and Haran-Ghera N. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci USA 98 (2001) 5181-5186
3. Katz O., Gil L., Lifshitz L., Prutchi-Sagiv S., Gassmann M., Mittelman M., et al. Erythropoietin enhances immune responses in mice. Eur J Immunol 37 (2007) 1584-1593
4. Prutchi-Sagiv S.P., Lifshitz L., Orkin R., Mittelman M., and Neumann D. Erythropoietin effects on dendritic cells: potential mediators in its function as an immunomodulator?. Exp Hematol 36 (2008) 1682-1690
5. Lifshitz L., Prutchi-Sagiv S., Avneon M., Gassmann M., Mittelman M., and Neumann D. Non-erythroid activities of erythropoietin: Functional effects on murine dendritic cells. Mol Immunol 46 (2009) 713-721
6. Ruschitzka F.T., Wenger R.H., Stallmach T., Quaschning T., de Wit C., Wagner K., et al. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc Natl Acad Sci USA 97 (2000) 11609-11613
7. Henke M., Laszig R., Rube C., Schafer U., Haase K.D., Schilcher B., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362 (2003) 1255-1260
8. Prutchi-Sagiv S., Golishevsky N., Oster H.S., Katz O., Cohen A., Naparstek E., et al. Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease?. Br J Haematol 135 (2006) 660-672